← All trials
NCT07142278
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2025
- Primary completion
- Apr 1, 2027
- Completion date
- Jul 31, 2027
- First posted
- Aug 26, 2025
- Last posted
- Oct 22, 2025
- Enrollment
- 24
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Nuravax, Inc.Lead sponsor
- National Institute on Aging (NIA)Collaborator
- Institute for Molecular MedicineCollaborator
- Nuravax, Inc.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.